

## Subject Index

- AAD. *See* Acidic activating domains  
ABP. *See* Androgen binding protein  
Acceptor protein, for thyroid receptor, 40  
Acidic activating domains (AAD), 30  
Acrosomal exocytosis, 460, 462, 467  
    A23187 and, 466  
    extracellular  $\text{Ca}^{2+}$  dependence of, 466  
    inhibition of, 466  
    M42 and, 466  
    QNB and, 466  
    tyrphostin RG50864 and, 466  
Acrosomal lamina (ALM), 242–245, 251, 255–256  
Acrosomal matrix (AMX), 241, 243–245, 255, 467–468  
Acrosomal membrane, 241, 243–245, 251, 255–256  
Acrosomal stabilizing factor, 367  
Acrosome  
    enzyme targeting to, 331, 336  
    EQ segment of, 241, 245–247, 249–251  
    functions during fertilization, 251, 255–256  
    structure-function relationships in, 240–256  
Acrosome formation, testosterone and, 272  
Acrosome-reacted sperm, and zona binding, 486  
Acrosome reaction. *See also* Spontaneous acrosome reaction; Zona-induced acrosome reaction  
A23187 and, 463, 466, 469  
and capacitation, 459–471  
characterization of, 459–560  
CTC fluorescence assay for, 460–461  
and fertilization, 459–471  
intracellular  $\text{Ca}^{2+}$  and, 461, 468–470  
M4 inhibition of, 462–463, 466, 470  
model, 467–470  
participants, 461–463  
pertussis toxin inhibition of, 463, 469  
PH-20 and, 489–490  
phorbol esters in, 463  
QNB inhibition of, 460–461, 463, 466, 469  
and sperm-zona binding, 486  
spontaneous, 460–461, 470–471, 479–480  
t complex and, 479  
tyrphostin RG50864 inhibition of, 466, 469  
ZP3 induction of, 462  
Acrosome reaction rate, and t complex sperm, 479  
Acrosome reaction stages  
    fenestrated (S3), 464–467, 470  
    intact (B;N+;F+), 464–469  
    poised (S1;N+;F+), 464–470  
    punctate (S2;N−;F−), 464–467, 470  
    reacted (AR), 464–467, 470  
Acrosome reaction stage transitions  
    blockage of, 460–463, 466, 469–470  
    enzymes in, 469–470  
    intracellular protein phosphorylation in, 468–470  
    signal transduction reactions in, 467–470  
Acrosome system, 204–205  
ACTH. *See* Adrenocorticotropin  
Actin filaments, in ectoplasmic specializations, 175, 178–186, 189–190, 192–193  
Activin, and Leydig cell steroidogenesis, 358  
Acute lymphoblastic leukemia phenotype, mutated *E2A* gene and, 300–301  
Adherens, 399. *See also* Cadherins; Cell adhesion molecules and principal cells, 404  
Adrenocorticotropin (ACTH), Leydig cell production of, 358  
Albumin, blood-to-lumen movement of, 371  
ALH. *See* Amplitude of lateral head displacement  
Amino acids, in epididymal fluids, 368  
Amplitude of lateral head displacement (ALH), of sperm motion, 417, 427–428  
AMX. *See* Acrosomal matrix  
Androgen action, in testis, 97–99  
Androgen antigrade movement  
    energy dependence of, 379–380  
    protein synthesis inhibition and, 380  
Androgen-binding protein (ABP)  
    bidirectional secretion of, 322–325  
    binding sites for, 270  
    in caput epididymal lumen, 375  
    endocytosis of, 271  
    in proluminal androgen movement, 375–381  
    Sertoli cell synthesis of, 272, 322–325,  
        328–329, 342, 357, 376  
    and sperm fertility, 381  
    steroid hormone transport by, 258  
Androgen-binding protein (ABP) levels  
    cyclic changes in, 319  
    reduction in, 322–325  
    in reproductive tract fluids, 372–374  
Androgen-binding protein (ABP) production  
    in cryptorchidism, 342–344  
    spermatid influence on, 342–347

- Androgen microenvironment, of maturing spermatozoa, 371–381  
Androgen production, by Leydig cells, 392  
Androgen proluminal movement, inhibition of, 378–380  
Androgen reabsorption, receptor-mediated endocytosis, 381  
Androgen receptors (AR)  
  cyclic concentration changes of, 318–319  
  first appearance of, 392  
  in Leydig cell progenitors, 157  
  as ligand-activated TF, 97  
  localization of, 98  
  in male sexual development, 56  
  molecular analysis of, 56–72  
  nuclear transport requirements of, 58–62  
  p59 association with, 33  
  in peritubular cells, 359  
  phosphorylation of, 62  
  and testicular target gene expression, 99  
  transcriptional activation domains of, 56–58  
Androgen replacement, and transcriptional gene expression, 389–391  
Androgens  
  antigrade movement of, 374–381  
  cell targets of, 98  
  and epididymal sperm maturation, 371–381  
  and gonadotropin secretion, 113  
  and Leydig cell differentiation, 155–157  
  mRNA-level regulation by, 98  
  and peritubular cell differentiation, 359  
  proluminal movement of, 374–381  
  and  $5\alpha$ -reduced androgens formation, 5  
  regional differences in concentration, 371–381  
  target gene regulation by, 97–99  
Androgen secretion, hemorchidectomy and, 133–141  
Antiandrogens. *See also* Androgen receptors  
  effects of, 60, 62  
Antimüllerian hormone (AMH). *See* Müllerian-inhibiting substance  
A23187, in acrosome reaction, 463, 466, 469  
ATP, and sperm motility reactivation, 439–440  
ATP level  
  and flagellar beat frequency, 440  
  ROS effect on, 440, 442  
Atresia, of female germ cells, 64  
Average-path velocity (VAP), of sperm motion, 417, 427  
*azh* mutation, 475  
Azoospermia  
  GnRH antagonist and, 118  
  in GnRH-immunized rats, 96  
  induced, 95–96  
  testosterone and, 4  
  via sustained estradiol-testosterone release, 5  
BCF. *See* Beat cross frequency  
Beat cross frequency (BCF), of sperm motion, 417–418, 427  
Blood-epididymal barrier, 370–371, 399, 404, 406  
*bouncy* mutation, 475–476  
Busulfan  
  and epididymal gene expression, 392–393  
  and proenkephalin mRNA, 392  
  seminiferous tubules disruption by, 322–324  
Cadherin mRNA  
  developmental changes in, 403–404  
  in epididymis, 400–407  
  longitudinal distribution of, 402–403  
Cadherins. *See also* Adherens; Cell adhesion molecules; Epithelial cadherin; Neural cadherin; Placental cadherin  
  characterization of, 399–400  
  in organogenesis, 399  
Calcium ion  
  and flagellar structure, 481  
  in spontaneous acrosome reaction, 471  
  in zona-induced acrosome reaction, 461, 468–470  
Calmodulin, 481  
Capacitation  
  and acrosome reaction, 459–471  
  characterization of, 459–560  
  and CTC fluorescence patterns, 460–469  
  PH-20 relocation during, 490  
  and t complex, 479  
Caput epididymis, morphological variation within, 384–385  
Carnitine, blood-to-lumen movement of, 370–371  
Carnitine concentration gradient, in epididymal fluids, 366  
Castration/androgen replacement, and transcriptional gene expression, 389–391  
CAT. *See* Chloramphenicol acetyltransferase  
Catalase, ROS destruction by, 436, 439  
Catecholamines  
  regressed testes responsiveness to, 145–146  
  steroidogenic response to, 145  
Cathepsin L, 319  
Cation-dependent MPRs, 330–332, 334–336  
Cation independent MPRs, 330–331, 334–336  
Cation ionophores, in acrosome reaction, 463, 466, 469  
Cell adhesion  
  in germ cell–Sertoli cell interactions, 347–349  
  in mammalian fertilization, 486  
Cell adhesion molecules (CAMs), 348. *See also* Cadherins  
  identification of, 491  
  in sperm-zona binding, 487, 491

- Cell-cell interactions  
potential regulatory agents in, 356  
in seminiferous epithelium, 327–329, 399  
and testis function regulation, 354–361  
types of, 354
- Cell-cell tight junctions  
adherence and, 399–400, 404  
calcium dependence of, 399–400  
and proluminal solute movement, 370–371  
zonula occludens provision by, 370
- Ceruloplasmin, copper transport by, 355
- Cervical mucus, and sperm motility, 412–413
- Chloramphenicol acetyltransferase (CAT)  
activity, antiandrogens and, 60, 62
- Chlortetracycline (CTC) probe  
and capacitated sperm fluorescence patterns,  
460–462, 464–469  
in capacitation assay, 460–461, 464
- Chromatin acceptor proteins, SR binding sites  
in, 40–42
- Chromatin acceptor sites, 40  
nuclear matrix model of, 41  
properties of, 41
- Clusterin (SGP-2), 79. *See also* Sulfated  
glycoprotein-2  
in epididymal lumen, 367
- Computer-assisted sperm analysis (CASA)  
sources of variation in, 427–430  
of sperm concentration, 430  
and sperm kinematics, 417–420, 424–426,  
430–434  
and sperm motility measurement, 419–420  
of sperm motion characteristics, 431–433  
technology, 426–427
- Computer-assisted sperm analysis (CASA) results  
counting chamber depth and, 429–430  
from semen, 430–433  
sperm concentration effect on, 427–429  
temperature effect on 427–428
- Conception mechanisms, West Point meeting  
on, 19, 22
- Contraception, via sustained testosterone-  
estradiol release, 5
- Cryptorchidism  
germ cell degeneration in, 341, 343  
and Leydig cell steroidogenesis, 358  
seminiferous tubule damage in, 358
- Sertoli cell function in, 342  
spermatogenesis alteration in, 445
- CTC. *See* Chlortetracycline
- Curvilinear velocity (VCL), of sperm motion,  
417, 427–429, 431–432
- Cyclophilin. *See* Peptidyl-prolyl *cis-trans*  
isomerase
- Cystatin, 319
- Cytoplasm from elongated spermatids (CES), in  
spermatid-Sertoli cell binding, 347–349
- Cytotoxic agents, seminiferous tubule damage  
by, 358
- DAG. *See* Diacylglycerol
- Desmosome-like junctions  
in germ cell-Sertoli cell interactions, 328  
of spermatids, 340–341
- DHT. *See* Dihydrotestosterone
- Diacylglycerol (DAG), and acrosome reaction  
stage transitions, 468–470
- Dihydrotestosterone (DHT)  
and E-Cad mRNA concentrations, 406  
and increased testosterone production,  
155–157  
potency enhancement of, 157–160  
in reproductive tract fluids, 372–374  
and spermatogenesis maintenance, 93–94  
testosterone conversion to, 371–372  
and testosterone secretion, 14
- DNA-binding elements, for TFs, 37
- DNA loop domains, 164–166  
and nuclear matrix attachments, 166
- DNA mini-loop domains, nuclear annulus  
attachment of, 167–173
- DNA organization  
in hamster sperm nucleus, 164–173  
levels of, 172–173  
in somatic cells, 164–165, 172–173
- cDNA probes, 401
- DNA-TF-SR interaction model, 39
- Doxorubicin, seminiferous tubules disruption  
by, 322–324
- Dynein  
in sperm flagella, 410
- E2. *See* Estradiol
- E-Cad. *See* Epithelial cadherin
- Ecdysone, 26, 42
- Ectoplasmic specializations  
actin filaments in, 175, 178–186, 189–190,  
192–193  
domains of, 179  
fimbrin in, 181, 184  
nature of, 175  
proteins associated with, 180–181, 184  
of spermatids, 328, 340–341
- Ectoplasmic specializations function  
adhesion hypothesis of, 190–192  
historical perspective of, 186–190  
intermediate filament hypothesis of, 196  
microtubule hypothesis of, 192–196  
in positioning spermatogenic cells, 192
- Ectoplasmic specializations structure, 175–179  
actin zone, 180–184  
cytoplasmic domain, 185–186  
ectoplasmic reticulum domain, 185  
ectoplasmic reticulum-related zone, 184

- extracellular domain, 179  
integral membrane domain, 179  
model of, 178–179  
plasma membrane-related zone, 180
- EDS. *See* Ethylene dimethanesulfonate
- EGF. *See* Epidermal growth factor
- Embryonic survival  
frozen semen and, 455–456  
heat-stressed males and, 456  
intrascrotal temperature and, 453–457
- $\beta$ BEND. *See*  $\beta$ -Endorphin
- Endocrine infertility, gonadotropin hormones and, 107
- Endocytic apparatus structure, during spermatogenesis, 263–265
- Endocytic pathways, in monkey germ cells, 265–269
- Endocytosis  
and luminal androgen reabsorption, 381  
of M6P-containing glycoproteins, 334–336  
M6P receptor-mediated, 332–334
- $\beta$ -Endorphin ( $\beta$ BEND)  
FSH inhibition by, 358  
Leydig cell production of, 358
- Epidermal growth factor (EGF), 355, 357
- Epididymal development, non-androgen testicular factors and, 389
- Epididymal fluids  
concentration gradients in, 364–368  
flow rate of, 368–369  
protein concentration in, 366
- Epididymal gene expression  
busulfan effects on, 392–393  
spermatozoan regulation of, 392–393
- Epididymal intraluminal fluids, 364–368
- Epididymal microenvironment, 368–369
- Epididymal mRNA levels, 391
- Epididymal proteins  
region specific, 367  
species specific, 367
- Epididymal sperm maturation, 371–381
- Epididymis  
ABP concentrations in, 372–374  
androgen microenvironment of, 5  
as androgen target tissue, 371–381  
fluid movement through, 368–370  
regulated gene expression in, 384–397  
temperature-dependent functions of, 456
- Epithelial cadherin (E-Cad) mRNA  
developmental changes in, 403, 405–407  
DHT and, 406  
epididymal distribution of, 402–407
- EQ. *See* Equatorial segment
- Equatorial segment (EQ), 467–468
- ER. *See* Estrogen receptor
- Estradiol (E2)  
LH secretion inhibition by, 4
- spermatozoan binding sites for, 258  
and sperm number, 3
- Estradiol (E2) feedback, in gonadotropin production, 130
- Estrogen, steroidogenesis inhibition by, 358
- Estrogen receptor (ER), 28–30  
chromatin acceptor proteins for, 42  
hsp90 binding with, 32–33  
and nuclear localization, 36  
p59 protein association with, 33
- Ethylene dimethanesulfonate (EDS) and ABP levels, 323
- Leydig cell elimination by, 95, 155, 322
- Fecundability  
abnormalities preventing, 424  
predictors of, 424
- Feedback inhibition, of testosterone synthesis, 5
- Female germ cells  
atresia of, 64  
meiosis in, 64–67  
and X chromosome behavior, 68
- Fertility  
with frozen semen, 446–447, 453–456  
intrascrotal temperature and, 452–453  
in PTU-treated rats, 126–127
- Fertilization  
acrosome reaction and, 459–471  
*bouncy* and, 476  
frozen semen and, 453  
M42 inhibition of, 462  
mutagenesis and, 476  
sperm motility and, 410–411
- Fertilization ability  
gene interactions in, 477  
mutations in, 476–483
- Fertilization defects, insertional mutagenesis in, 476
- Fetal meiotic decisions, 66–67
- Fibrous sheath (FS), of mammalian spermatozoon cytoskeleton, 203
- Fibrous sheath (FS) proteins, 224–225  
characterization of, 227–229, 234–235  
cytoskeletal characteristics of, 231–233  
developmental appearance of, 229–231, 235–236  
and intermediate filament proteins, 236–238
- Fimbrin, in ectoplasmic specializations, 181, 184
- Flagellar beat frequency, ATP and, 440
- Flagellar calcium sensitivity, t complex and, 481
- Flagellar morphology mutations affecting, 481–482
- Flagellar motion  
in hyperactivation, 414  
mechanism of, 409–410  
photomicrographic study of, 419  
in semen/cervical mucus, 412–413

- Follicle-stimulating hormone (FSH), 8  
and ABP secretion, 376  
and Leydig cell differentiation, 153–154  
photoperiod-related Sertoli cell response to, 146–147  
and primate testicular function, 107, 115–116  
and RB/CES binding, 348  
and Sertoli cell–germ cell interactions, 348, 357  
and spermatogenesis maintenance, 92–93,  
96–97, 103  
spermatogenesis regulation by, 107, 129  
and spermatogenesis reinitiation, 118  
and testicular cell–cell interactions, 360  
testicular effects of, 110, 129
- Follicle-stimulating hormone receptor (FSHR)  
levels, cyclic changes in, 317–319
- Fractal dimension, and sperm head trajectory shape, 418
- FS. *See* Fibrous sheath
- FSH. *See* Follicle-stimulating hormone
- FSHR. *See* Follicle-stimulating hormone receptor
- Fura-2, and sperm fluorescence patterns, 466
- Galactosyltransferase (GT)  
as CAM, 487  
in sperm–zona binding, 489–490  
in t/+ sperm populations, 479
- Gametogenesis  
FSH in, 116  
sexual dimorphism in, 64–66
- Gap-junctions, in spermatid–Sertoli cell interactions, 328, 341
- Gene expression  
developmental aspects of, 392  
epididymal sites of, 385–388  
regional epididymal specificity of, 385–388  
steroid action on, 47  
transcriptional regulation of, 389–393
- Gene regulation  
cell-type specific, 38  
TF-SR interaction in, 39–40
- Genetic defects, germ cell depletion in, 322–324
- Gene transcriptional activity, SR and, 29
- Germ cell. *See also* Sperm; Spermatid;  
Spermatozoa
- Germ-cell differentiation  
Sertoli cells and, 66  
XX chromosome constitution and, 66–67  
Y chromosome presence and, 66–67
- Germ cell number, agents causing reduction in, 322–325
- Germ cells  
in adrenal cortex, 66  
cell–cell interaction effects on, 328  
M6P receptor-mediated endocytosis in, 332–334
- Germ cell–Sertoli cell interactions  
and ABP bidirectional secretion, 322–325  
adhesion factors in, 347–349  
desmosome-like junctions in, 328  
effects of, 327–329  
mechanisms of, 347–349  
mediators of, 328, 341, 347–349  
MPR mediation of, 327–336
- Germ-cell sex, first appearance of, 66
- Germline cells, Sertoli cell effects on, 355
- GH. *See* Growth hormone
- Glucocorticoid receptor (GR), 28–31  
hsp90 stabilization of, 32  
p59 protein association with, 33
- Glucose-6-phosphate dehydrogenase (G6PD),  
X chromosome inactivation and, 68–69
- Glutathione peroxidase/reductase system, ROS destruction by, 436
- Glycerylphosphorylcholine (GPC), progressive epididymal concentrations of, 364, 366
- Glycoprotein ZP3  
in acrosome reaction stage transitions, 469–470  
in induced acrosome reaction, 462  
and signal transduction chain, 464–466  
sperm membrane receptors for, 462–463, 469
- Glycoprotein ZP3 modifications, TPA treatment and, 465–466
- Gonadotropin-releasing hormone (GnRH), and spermatogenesis, 92, 110
- Gonadotropin-releasing hormone (GnRH)  
antagonist  
and azoospermia, 113  
and DHT/testicular testosterone concentrations, 114–115  
gametogenesis inhibition by, 112
- GPC. *See* Glycerylphosphorylcholine
- Gpd gene, X chromosome inactivation and, 69
- G proteins  
pertussis toxin inactivation of, 463  
in zona-induced acrosome reaction, 463, 469–470
- GR. *See* Glucocorticoid receptor
- Growth hormone (GH), 8  
and mouse germ cell development, 107
- G6PD. *See* Glucose-6-phosphate dehydrogenase
- GTP-binding regulatory proteins. *See* G proteins
- hCG. *See* Human chorionic gonadotropin
- Heat shock protein (hsp90)  
functions of, 33
- GR stabilization by, 32  
and nuclear localization, 36  
SR interaction with, 28, 32–34
- Hemorchidectomy  
and androgen/LH secretion, 133–141  
Sertoli cell number reduction by, 324

- hMG. *See* Human menopausal gonadotropin  
Homeobox genes (Hox)  
characterization of, 300–304, 309  
and differentiation regulation, 300–301  
as TFs, 300
- Hormone response element (HRE), 35
- hotfoot mutation, 475–476
- HOX* genes. *See also* Homeobox genes  
retinoic acid and, 304
- Hox* genes expression  
and embryogenic structural organization, 304–305  
pattern of, 304  
tissue specificity of, 305–308
- HPRT. *See* Hypoxanthine phosphoribosyl transferase
- Hprt* gene, X chromosome inactivation and, 68–69
- Human chorionic gonadotropin (hCG)  
effects of, 108  
and spermatogenesis, 116  
and testosterone spermatogenesis role, 113
- Human menopausal gonadotropin (hMG), and  
gametogenesis, 110, 116
- Human sex steroid-binding protein (hSBP).  
*See also* Sex steroid-binding protein  
endocytosis of, 265–273  
purification of, 260
- Hyperactivation, 480–481  
CASA analysis of, 420  
as fertilizing capacity biomarker, 415  
flagellar beats in, 414  
sperm exhibition of, 413–415
- Hypogonadotropism, hCG therapy in, 116
- Hypothyroidism. *See also* Transient hypothyroidism  
PTU induction of, 124–128  
and testicular development, 123–130
- Hypoxanthine phosphoribosyl transferase (HPRT), X chromosome inactivation and, 68–69
- IAM. *See* Inner acrosomal membrane
- IB15 gene, 389  
and PPI, 385
- IB15 mRNA  
distribution of, 385–386  
levels distribution, 392
- Idiopathic infertility, ROS formation and, 436
- IGF. *See* Insulin-like growth factors
- IgG. *See* Immunoglobulin G
- Immobilin, in epididymal lumen, 367
- Immunoglobulin G (IgG), blood-to-lumen movement of, 371
- Implantation fossa, 165–166, 173
- Infection, and sperm function damage, 438–439
- Inhibin, 319, 329  
and Leydig cell steroidogenesis, 154, 358  
PMo5-stimulated production of, 100
- Inhibin production  
by Sertoli cells, 358  
spermatid influence on, 342–343
- Inner acrosomal membrane (IAM), 467–468  
PH-20 and, 490
- Inositol  
blood-to-lumen movement of, 371  
in epididymal fluids, 366
- Insulin-like growth factor-I (IGF-I)  
and androgen production, 160–161  
and Leydig cell steroidogenesis, 154  
peritubular cell production of, 357  
Sertoli cell production of, 355  
stimulatory effects of, 357  
T3-stimulated production of, 123
- Insulin-like growth factor-II (IGF-II)  
CI-MPR binding to, 330  
in testes, 335
- Interleukin-1 (IL-1), Sertoli cell production of, 355, 358–359
- Intrascrotal temperature  
and embryonic survival, 453–457  
and fertility, 452–453, 455–457  
and male infertility, 445–446  
scrotal insulation and, 447–448  
and spermatogenesis, 445–446, 455  
and sperm motility, 449–451, 455–457  
and TSC, 449–451, 455–457
- Ion concentration gradient, in epididymal fluids, 364–365
- Ion reabsorption, in epididymal fluids, 365–366
- Ischemia, and ABP levels, 322–323
- $\alpha$ -Lactalbumin-like protein, in epididymal lumen, 367
- Lactate production, puberty delay and, 146–147
- Lag phase, following SR-binding, 27
- Leu-enkephalin. *See* Proenkephalin pentapeptides
- Leydig cell differentiation  
androgen involvement in, 155–157  
FSH/LH promotion of, 153–154  
hCG facilitation of, 154  
hormonal control of, 152–161
- Leydig cell function, 144–146  
regulation of, 1, 4
- Leydig cell morphology  
agents altering, 358
- LH and, 9  
testosterone secretion inhibition and, 7–8
- Leydig cell–peritubular cell interactions, 359
- Leydig cell peroxisomes, and testosterone production, 9–10
- Leydig cell population, mesenchymal cells and, 11–12, 14

- Leydig cell progenitors  
ARs in, 157, 161  
enhanced DHT action on, 157–160  
IGF-I stimulatory effect on, 160–161
- Leydig cells  
activin/inhibin production by, 358  
androgen production by, 153, 392  
ARs in, 98  
early study of, 17  
EDS elimination of, 95, 155, 322  
estrogen production by, 358  
photoperiod-related changes in, 144–146  
POMC derivatives produced by, 358  
progenitors of, 152–153  
5 $\alpha$ -reduced androgen production by, 153  
regulation of, 5–7  
Sertoli cell influence on, 358–359  
smooth endoplasmic reticulum of, 7–8  
and spermatogenesis, 94–95, 99, 103, 107  
in testicular function, 354  
testosterone production by, 5, 9–10, 81,  
90, 399
- Leydig cell–Sertoli cell interactions, 358–359
- Leydig cell steroidogenesis  
Sertoli cell secretions and, 358  
TGF- $\beta$  inhibition of, 328
- LH. *See* Luteinizing hormone
- LHRH. *See* Luteinizing hormone releasing hormone
- LIN. *See* Linearity
- Linearity (LIN, L), of sperm motion, 417,  
427–429, 431–432
- Lonidamine, seminiferous tubules disruption by, 322–323
- Luteinizing hormone (LH)  
and Leydig cell differentiation, 153–154  
and Leydig cell smooth endoplasmic reticulum, 8  
and progesterone-testosterone conversion, 8–9  
spermatogenesis regulation by, 107, 129  
steroidogenesis inhibition by, 7–8  
and testicular cell-cell interactions, 359–360  
and testosterone production, 90
- Luteinizing hormone (LH) suppression, and azoospermia, 95–96
- Luteinizing hormone releasing hormone (LHRH)  
and germ cell reduction, 322–323  
and Sertoli cell number reduction, 322–324
- Luteinizing hormone secretion  
following hemorchidectomy, 133–141  
testosterone inhibition of, 4
- Lysozyme gene, and SREs, 37
- MAD. *See* Mean angle of deviation
- Major excreted protein (MEP)  
factors stimulating synthesis of, 328–329  
procatepsin L as, 328–329
- Male fertility  
assessment problems, 425  
sperm motility and, 409  
testosterone-estradiol temporal effects on, 4
- Male germ cells  
meiosis of, 64–70  
X chromosome inactivation in, 67–70
- Male infertility  
FSH/hCG/hMG treatment for, 116  
intrascrotal temperature and, 445–446  
ROS formation and, 436–437  
sperm motility disorders in, 424–426
- Mammalian testis, perfusion of, 1–2
- Mannose 6-phosphate (M6P) glycoproteins  
Sertoli cell secretion of, 334–335
- Mannose 6-phosphate receptor (CI-MPR)  
endocytosis mediation by, 330  
growth factors binding to, 330  
and IGF-II receptor, 330, 335  
Sertoli cell synthesis of, 331
- Mannose 6-phosphate receptor glycoproteins, and endocytosis, 334–336
- Mannose 6-phosphate receptor-mediated endocytosis, 332–334
- Mannose 6-phosphate receptors (MPRs)  
cation-dependent (CD) form, 329–332,  
334–36  
cation-independent (CI) form, 329–331,  
334–336  
characteristics of, 329–330  
as germ cell–Sertoli cell interaction mediators, 327–336  
in germ cells/Sertoli cells, 330–332  
and lysosomes, 329
- Mean angle of deviation (MAD), CASA analysis of, 432
- Meiosis  
dimorphism of, 67–68  
of female germ cells, 64–67  
of male germ cells, 64–70
- $\alpha$ -Melanocyte stimulating hormone ( $\alpha$ -MSH),  
Leydig cell production of, 358
- MEP. *See* Major excreted protein
- Metabolic inhibitors, and androgen proluminal movement, 378–380
- Met-enkephalin. *See* Proenkephalin pentapeptides
- 3-O-Methyl-D-glucos (30 MG), blood-to-lumen movement of, 371
- M42 monoclonal antibody  
and acrosomal exocytosis, 466  
acrosome reaction inhibition by, 462–463,  
466, 470
- MIS. *See* Müllerian-inhibiting substance
- MMTV. *See* Mouse mammary tumor virus
- Mouse mammary tumor virus (MMTV), SREs in, 31, 37–38
- MPR. *See* Mannose 6-phosphate receptor

- α-MSH.** *See* α-Melanocyte stimulating hormone  
**M6P.** *See* Mannose-6-phosphate  
**Müllerian-inhibiting substance (MIS)**  
characterization of, 77, 329  
and gonadal masculinization, 74–75  
production of, 77–79  
and testicular differentiation, 74–82, 85–86  
**Mutations**  
and fertilization defects, 476  
in fertilization studies, 474–475  
and male fertility, 474  
and sperm-egg interactions, 476, 478  
and sperm fertilizing ability, 476–483  
and sperm function, 474–483  
and sperm head morphology, 475  
and sperm motility, 475, 479–481
- NAP.** *See* Nucleoacidic protein  
**National Institute of Child Health and Human Development (NICHD) Workshop on the Testis,** 322  
**NDAA.** *See* *N-(n-dodecyl)-9-aminoacridine*  
**Nerve growth factor (NGF),** 356–357  
**Neural cadherin (N-cad),** in testis/seminaliferous tubules, 348  
**Neutrophil concentration, and sperm function damage,** 438–439  
**New York Academy of Sciences Meeting (1952),** 19  
**Nexin, in sperm flagella,** 410  
**NGF.** *See* Nerve growth factor  
**Nigericin, in acrosome stage transitions,** 466  
***N-(n-dodecyl)-9-aminoacridine (NDAA),*** and sperm fluorescence patterns, 464  
**Non-hsp proteins, and unactivated PR complex,** 33  
**Nuclear annulus**  
DNA loop association with, 165–173  
DNA mini-loops attachment to, 167–173  
structure/position of, 166–167  
**Nuclear localization, ER-hsp90 interaction and,** 36  
**Nuclear localization signal**  
for SRs, 36  
and zinc finger region, 35–36  
**Nuclear matrix, DNA loop domains specific sites in,** 166  
**Nucleoacidic protein (NAP),** 40–42
- OAM.** *See* Outer acrosomal membrane  
**ODC.** *See* Ornithine decarboxylase  
**ODF.** *See* Outer dense fibers  
**3OMG.** *See* 3-O-Methyl-D-glucose  
**Ornithine decarboxylase (ODC) production, testosterone effect on,** 99–100  
**Outer acrosomal membrane (OAM),** 467–498
- Outer dense fiber proteins**  
developmental expression of, 209–210  
intracellular localization of, 211–214  
**Outer dense fibers (ODF)**  
antibodies to, 207–208  
formation of, 219–222  
isolation of, 204–205  
of mammalian spermatozoon cytoskeleton, 203–214  
polypeptide composition of, 205–206  
structure of, 204
- Paracrine factors**  
peritubular myoid cell production of, 357–358  
in Sertoli cell function, 340  
Sertoli cell production of, 355–357  
**Paracrine factors mediation, of testicular cell-cell interactions,** 359–361  
**pep.** *See* Peptidyl-prolyl cis-trans isomerase  
**Peptidyl-prolyl cis-trans isomerase (PPI),** 385–386  
constitutive expression of, 390–391, 397  
function of, 394  
principal cell secretion of, 385  
**Peptidyl-prolyl cis-trans isomerase (PPI) mRNA,** 385–386  
distribution of, 385–386  
**Peptidyl-prolyl cis-trans isomerase (PPI) mRNA levels**  
androgen replacement and, 389–391  
in epididymis, 386  
**Perforatorial proteins**  
developmental expression of, 209–210  
distributional pattern of, 214–219  
**Perforatorium**  
antibodies to, 208  
formation of, 219–222  
isolation of, 204–205  
polypeptide composition of, 205–206  
structure of, 204
- Perinuclear theca (PT), of mammalian spermatozoon**  
cytoskeleton, 203  
**Peritubular cell-Sertoli cell interactions,** 357–358  
**Peritubular myoid cells**  
EGF receptors on, 357  
growth factors produced by, 359  
Leydig cell interactions with, 359  
paracrine factors produced by, 357–358  
PModS secretion by, 100, 359  
in testis cytoarchitecture, 354  
testosterone action mediation by, 98, 100  
**Pertussis toxin, in acrosome reaction blockage,** 463, 469  
**p56, ZP3-binding activity of,** 462

- PGK.** *See* Phosphoglycerate kinase  
**Pgk** genes, in spermatogenic cells, 69  
**PH-20**  
in acrosome-reacted sperm-zona binding, 488  
in epididymal maturation, 489-490  
modification of, 489-490  
post-testicular changes in, 489  
relocation during capacitation, 490
- pH**  
and acrosome reaction, 468  
of intraluminal fluids, 366  
of spermatozoa, 368  
and sperm fluorescence pattern changes, 464
- pH probes**, in sperm capacitation, 464
- Phorbol esters**, and acrosome reaction, 463
- Phosphoglycerate kinase (PGK)**, X chromosome inactivation and, 68-69
- Phospholipase C (PL-C)**, in zona-induced acrosome reaction, 463, 469-470
- Photoperiod-related changes**  
in FSH release, 146-147  
in Leydig cells, 144-146  
in testicular function, 143-144
- Placental cadherin (P-Cad)** mRNA concentration changes, 406  
developmental changes in, 403-407  
epididymal distribution of, 402-407
- Plakoglobin**, in ectoplasmic specializations, 180
- Plasma membrane (PM)**, 467-468
- Plasminogen activator production**, testosterone effect on, 99
- PL-C.** *See* Phospholipase C
- PM.** *See* Plasma membrane
- PModS**  
androgen control of, 357  
forms of, 357
- Sertoli cell regulation by, 100, 357-359
- PMSG.** *See* Pregnant mare serum gonadotropin (TK)  
in acrosome reaction, 462, 469-470  
in spontaneous acrosome reaction, 471  
as ZP3 receptor, 462, 469-470
- Population kinetics**, in fluorescence pattern loss, 464-465
- PR.** *See* Progesterone receptor
- Pregnant mare serum gonadotropin (PMSG)**, and gametogenesis, 110
- Pregnenolone**, testosterone biosynthesis from, 6
- Principal cell**  
protein transcripts, 386-388
- Principal cells**  
characterization of, 384-385  
epididymis-specific proteins secreted by, 385  
tight junctions between, 404
- Procathepsin L (cyclic protein 2)**, Sertoli cell secretion of, 328-329
- Proenkephalin**  
functional role of, 393-397  
principal cell secretion of, 385
- Proenkephalin mRNA levels**  
busulfan effect on, 392  
castration/androgen replacement and, 390  
regional differences in, 386  
time course of, 391
- Proenkephalin pentapeptides**, 385  
epididymal localization of, 395-397
- Progesterone**, spermatozoan binding sites for, 258
- Progesterone receptor (PR)**, 28-29  
chromatin acceptor sites for, 40-42  
higher order structure of, 34  
hsp90 binding with, 32-33  
p59 protein association with, 33
- Proliferin**, CI-MPR binding to, 330
- 6-Propyl-2-thiouracil (PTU)**  
and body growth, 124  
and hypothyroidism, 124  
and testis size/sperm production, 127-128
- Prostatic hyperplasia**, androgen dependence of, 5
- Protamine mRNA expression**  
in spermatics, 278, 285-287, 297-298  
timing of, 277-278, 280-285, 289, 292, 294
- Protein B/C**  
androgen-dependent gene transcription, 389  
function of, 394  
principal cell secretion of, 385
- Protein B/C mRNA levels**  
castration/androgen replacement and, 389-390  
time course of, 392
- Protein D/E**  
androgen-dependent gene transcription, 389  
carboxypeptidase Y homology with, 394  
principal cell secretion of, 385
- Protein D/E mRNA levels**  
castration/androgen replacement and, 389-390  
time course of, 392
- Protein kinase C (PK-C)**, in zona-induced acrosome reaction, 463, 468-470
- Protein microenvironment**, and spermatozoan development, 366
- Proto-oncogenes**, as regulatory genes, 42-43
- PT.** *See* Perinuclear theca
- PTU.** *See* Propyl-2-thiouracil
- QNB.** *See* 3-Quinuclidinyl benzilate
- 3-Quinuclidinyl benzilate (QNB)**  
and acrosome reaction, 460-463, 466  
B-to-S1 transition blockage by, 469
- R.** *See* Receptor proteins
- Radiation**  
and ABP levels, 322-323, 344-347  
seminiferous tubule damage by, 358  
and Sertoli cells, 344-347

- Radixin, in ectoplasmic specializations, 180  
RAR. *See* Retinoic acid receptor  
RB. *See* Residual bodies  
RBF. *See* Receptor binding factors  
Reactive oxygen species (ROS)  
  enzymes destroying, 436  
  and human spermatozoa, 436–442  
  toxicity to spermatozoa of, 436  
Reactive oxygen species (ROS) effect  
  on spermatozoan ATP level, 439–440, 442  
  on sperm motility/viability, 439–441  
Reactive oxygen species (ROS) formation  
  and idiopathic infertility, 436  
  in infertile males, 437  
  by neutrophils, 438–439  
  sperm washing procedures effect on, 438  
Reactive oxygen species (ROS) scavengers, 441  
  and X + XO treated spermatozoa, 442  
Receptor binding factors (RBF), 41–42  
Receptor domains, 28  
Receptor phosphorylation, 34–35  
  and cytosolic PR, 33  
5α-Reductase, in testosterone-to-DHT conversion, 371–372  
Regulatory genes  
  classes of, 44  
  early genes as, 42–43, 47  
Regulatory gene transcription, SR action on, 45–47  
Reproduction and Human Welfare, Ford Foundation Report on, 22, 24  
Residual bodies (RB), in spermatid-Sertoli cell binding, 341, 347–349  
Retinoic acid receptor (RAR) levels, in spermatogenesis, 316–317  
RU486, AR agonist action of, 62
- SCP-2. *See* Sterol carrier protein-2  
Scrotal insulation. *See also* Intrascrotal temperature  
  and rectal temperatures, 448, 455–456  
  and respiratory rates, 448, 455–456  
  and spermatozoan metabolism, 456  
SDS. *See* Sodium dodecyl sulfate  
Semen analysis  
  CASA technology and, 424–426  
  frozen semen and, 447, 452–453  
  motion characteristics, 431–433  
  problem areas in, 425–426  
  semen collection for, 426  
  sperm concentration estimates, 430  
Seminiferous epithelium cycle, receptor expression during, 313–320  
Seminiferous growth factor (SGF), 360  
Seminiferous tubule disruption  
  agents causing, 322–324  
  and Leydig cell morphology, 358
- Seminiferous tubule fluid (STF), testosterone concentration in, 91, 94, 96, 98–99, 101, 115  
Seminiferous tubules, hCG effect on, 108  
Sertoli cell function  
  paracrine factors in, 340  
  PModS effects on, 359  
  spermatid regulation of, 340–349  
Sertoli cell–germ cell interactions, 355–357.  
  *See also* Germ cell–Sertoli cell interactions  
desmosome-like junctions in, 328  
NGF in, 356–357  
Sertoli cell products, functional mode distribution of, 320  
Sertoli cell response, to testosterone, 100, 103  
Sertoli cells, 18, 22, 71  
  and ABP synthesis, 272, 322–325, 328–329, 342, 355, 376  
ARs in, 98  
Cell-cell interaction effects on, 328  
  in copper transport, 355  
  cyclic changes in, 313–314  
  cyclic RAR levels in, 316  
  ectoplasmic specializations in, 175–197, 348  
  functional modes of, 315–320  
  and germ-cell differentiation, 66, 328  
  germinal cell interaction with, 355–357  
  growth factors produced by, 355–357  
  IGF-I production by, 123  
  IL-1 production by, 355, 358–359  
  in iron transport, 315, 355  
  lactate production by, 146–147, 355  
  Leydig cell interaction with, 358–359  
  M6P receptor-mediated endocytosis in, 332–334  
  neonatal LHRH antiserum reduction of, 322–324  
  peritubular cell interaction with, 357–358  
  photoperiod-related changes in, 146–147  
  PModS stimulation of, 100  
  pyruvate production by, 355  
  radiation effects on, 344–347  
  RB/CES binding to, 347–349  
  roles of, 327–328  
  SGP-2 production by, 79–81, 100–101  
  spermatid action on, 347–349  
  structural relationships with spermatids, 340–341  
  sulfated glycoprotein secretion by, 331, 335  
  testicular cadherin in, 348  
  in testis cytoarchitecture, 354  
  transferrin synthesis by, 315, 328, 355  
  T3 receptors in, 123  
Sertoli cell-secreted proteins, 100, 327–329  
  M6P-containing glycoproteins, 334–336  
  testosterone action on, 99  
Sertoli cell–spermatid binding, CES and, 347–349

- Sex steroid-binding protein (SBP). *See also* Human sex steroid-binding protein  
endocytosis of, 258–273  
steroid hormone transport by, 258
- SGF. *See* Seminiferous growth factor
- SGP-2. *See* Sulfated glycoprotein-2
- Signal transduction chain  
in acrosome reaction stage transitions, 467–470
- ZP3-initiated, 464–466
- Single cell kinetics, in fluorescence pattern loss, 464–465
- Sodium dodecyl sulfate (SDS), in cytoskeletal isolation, 204
- Somatomedin-C. *See* Insulin-like growth factor-I
- Sperm. *See also* Germ cell; Spermatid; Spermatozoa  
Spermatid numbers, and Sertoli cell function parameters, 344–347
- Spermats  
desmosome-like junctions in, 340–341  
structural relationships with Sertoli cells, 340–341
- Spermatogenesis  
androgen regulation of, 90–103  
cyclic FSH mRNA levels in, 317–319  
early studies of, 18–19  
in GnRH-immunized rats, 94–96  
heat alteration of, 445–446  
homeobox genes expression in, 300–309  
initiation of, 107–110  
intrascrotal temperature and, 445–446  
Leydig cell tumor and, 110  
maintenance of, 107–108, 110–116  
morphological events in, 340–341  
nonandrogenic Leydig cell products and, 94–95  
peritubular cell–Sertoli cell interaction and, 359  
pituitary hormones dependence of, 107  
in primates, 107–119  
protamine mRNA transcription in, 277–278  
qualitatively/quantitatively normal, 108  
RAR in, 316–317  
reinitiation of, 108, 116–118  
SBPs role in, 272  
in seasonal breeders, 143–146  
seminiferous epithelium cycle in, 313–320  
Sertoli cell changes in, 313  
sex chromosomes role in, 64–72  
and testicular testosterone, 114–115  
testosterone-dependence of, 90  
testosterone maintenance of, 91–95  
testosterone restoration of, 95–97  
transferrin receptor mRNA levels in, 315–319  
vitamin A deficiency and, 316–317  
X chromosome inactivation in, 67–70  
in XO,Sxr males, 70–71  
Y chromosome role in, 66, 70–71
- Spermatogenesis initiation  
FSH role in, 110  
LH in, 108  
testosterone role in, 108–110
- Spermatogenesis maintenance  
FSH and, 92–93  
testosterone concentration and, 91–95
- Spermatogenesis modifications, scrotal temperature and, 446–457
- Spermatogenesis suppression  
by GnRH antagonist, 112  
and testicular somatic cell control/function, 143–149
- testosterone-estradiol synergism and, 4
- Spermatogenic cell endocytosis, of M6P-glycoproteins, 334–336
- Spermatozoa. *See also* Germ cell; Sperm; Spermatid  
in epididymal microenvironments, 364–381  
lipid peroxidation sensitivity of, 436  
in proenkephalin gene expression regulation, 392–393
- steroid-binding sites on, 258  
structural domains in, 240
- Spermatozoan cytoskeletal elements  
biogenesis of, 203–222  
components of, 203–204  
SDS-insoluble proteins of, 203
- Sperm concentration gradient, in epididymal fluids, 365–366
- Sperm dysfunction models  
*azh*, 475  
*bouncy*, 475–476  
*hotfoot*, 475–476  
*t* complex, 475–482
- Sperm–egg interactions  
defects in, 476, 478–479  
*t* complex and, 478–479, 481
- Sperm exocytosis, initiation of, 486
- Sperm fertility, ABP and, 381
- Sperm flagella, structure of, 409–411
- Sperm fluorescence patterns  
with CTC, 460–462, 464–469  
with fura-2, 466–467  
with NDAA, 464, 467
- Sperm function  
genetics of, 4744–483  
neutrophil/infection damage to, 438–439
- Sperm kinematics, 416–418. *See also* Sperm motility  
CASA and, 417–420, 424–426, 430–434
- Sperm morphology  
mutations in, 475
- Sperm motility  
ATP reactivation of, 439–440  
biological importance of, 410–412  
characteristics of, 409–420

- characterization of, 416–418  
components of, 416  
in epididymis, 367–368  
female tract properties and, 411  
generation of, 409–410  
hyperactivated, 413–415  
intrascrotal temperature and, 449–451  
and male fertility, 409  
measurement of, 419–420  
mutations in, 479–482  
in semen, 412–413  
and t complex genes, 475, 478–482  
in uterus/oviduct, 413–415  
velocities of, 417–418  
 $X + X0$  effect on, 439, 442
- Sperm motility measurement  
by CASA, 419–420  
indirect methods for, 419
- Sperm motility parameters, definition of, 417–418
- Sperm number  
combined testosterone-estradiol effect on, 3  
estradiol effect on, 3  
testosterone effect on, 3
- Sperm production  
pituitary hormone replacement and, 424  
in PTU-treated rats, 126
- Sperm proteins  
PH-20, 488–490  
post-testicular modification of, 486–491
- Sperm QNB binding protein (SQBP)  
as  $\text{Ca}^{2+}$  channel, 463  
and intracellular  $\text{Ca}^{2+}$ , 469
- Sperm-zona binding  
acrosome reaction and, 486  
CAMs in, 487  
PH-20 in, 488
- Spontaneous acrosome reaction, 479–480.  
*See also* Acrosome reaction; Zona-induced acrosome reaction
- Sputnik, impact of, 19
- Spy gene, 71
- SQBP. *See* Sperm QNB binding protein
- SR. *See* Steroid receptor
- SRU. *See* Steroid response unit
- SRY DNA sequence, as *TDF* gene candidate, 74
- Steel (*SI*) mutation, and sterility, 474
- Sterility, mutations causing, 474
- Steroid action  
basic mechanism of, 26–29  
cascade model of, 43–45  
on chromatin structure, 45  
on gene expression, 47
- Steroid-binding domain IV  
and hsp90 binding, 33  
and protein activity inhibition, 30
- Steroid hormone action, 35  
model of, 97
- Steroidogenesis inhibition, by LH, 7–8
- Steroid receptors (SR), 26–27, 29  
complex formation, 27
- DNA-binding domain (II and III), 28–30  
nuclear localization sequences of, 35–36  
primary structure of, 29–31  
protein interaction with, 32–34  
quaternary structure of, 31–34  
and regulatory gene transcription, 45–47  
steroid-binding domain (IV), 30–31  
TF interaction with, 37–38
- Steroid-response elements (SRE), 27–28, 31, 35, 46–47  
distribution of, 37  
palindromic structure of, 36  
SR binding to, 36–47
- Steroid response unit (SRU), 37
- Sterol carrier protein-2 (SCP-2), 10–11
- STR. *See* Straightness
- Straightline velocity (VSL), of sperm motion, 417, 427, 432
- Straightness (STR), of sperm motion, 417
- Sulfated glycoprotein-2 (SGP-2)  
characterization of, 79  
levels per testis of, 102–103  
production of, 79–81  
and testicular differentiation, 75–82, 85–86
- Superoxide dismutase, ROS destruction by, 436, 439
- Sustained release, of testosterone-estradiol, 4–5
- Ta3. *See* Triiodothyronine
- Ta4. *See* Thyroxine
- TAF. *See* Transcriptional activating function (TAF)
- t complex  
and acrosome reaction, 479  
chromosome locus of, 476  
and flagellar  $\text{Ca}^{2+}$  sensitivity, 481  
lethal factors in, 476  
and regulatory proteins, 479  
and sperm fertilizing ability, 476–479  
sperm genotypes in, 476–481  
and sperm motility, 475, 478–482  
and sperm transport, 478–479  
testis-expressed genes in, 477–478
- Tdy gene, and testicular differentiation, 74
- Testicular cell differentiation  
biochemical evidence for, 75–82  
SGP-2 and, 75–82, 85–86  
ultrastructural evidence for, 75
- Testicular changes, in PTU-treated rats, 125–126
- Testicular development  
thyroid hormones and, 122–124  
transient hypothyroidism and, 123–130
- Testicular differentiation, in XX mouse  
gonadal graft, 74–87

- Testicular function in primates  
  FSH effects on, 107, 115–116  
  testosterone effects on, 107–119
- Testicular macrophages  
  FSH-stimulated lactate production by, 148  
  seasonally-related decreases in, 147–148
- Testicular organomegaly, induction of, 124
- Testicular perfusion, 1–2  
  testosterone synthesis in, 3
- Testicular somatic cell function, spermatogenesis suppression and, 143–149
- Testicular temperature, and spermatogenesis, 445–446
- Testicular testosterone, in GnRH antagonist-treated monkeys, 114
- Testicular testosterone secretion, hCG and, 144–145
- Testis  
  androgen action in, 97–99  
  cadherin in, 348  
  cytoarchitectural cells of, 354
- Testis-expressed genes, in *t* complex, 477–478
- Testis growth, in PTU-treated rats, 125
- Testis research  
  landmarks in, 19–24  
    1949–1950, 17–19  
    1950–1975, 24
- Testosterone  
  and ABP secretion, 376  
  and acrosome formation, 272  
  and azoospermia, 4  
  biosynthetic pathways, 6  
  as effective testis androgen, 94  
  epididymal concentration gradient of, 371–373  
  and primate testicular function, 107, 129  
  in Sertoli cell function, 340  
  and spermatogenesis initiation, 108–110  
  and spermatogenesis maintenance, 110–116, 129  
  and spermatogenesis reinitiation, 116–118  
  spermatozoan binding sites for, 258  
  and sperm number, 3  
  and testicular cell differentiation, 81, 129  
  *in vitro* production of, 12–14
- Testosterone action  
  peritubular myoid cell mediation of, 98  
  Sertoli cell mediation of, 98  
  on Sertoli cell proteins, 99–103
- Testosterone concentration  
  and spermatogenesis maintenance, 91–95, 98  
  in STF, 91, 94, 96, 98–99, 101
- Testosterone levels, in PTU-treated rats, 127
- Testosterone metabolites, formation of, 5
- Testosterone production  
  by Leydig cell progenitors, 155–157  
  Leydig cells and, 5, 81, 90  
  LH stimulation of, 12–14
- Testosterone secretion  
  smooth endoplasmic reticulum amount and, 7  
  species differences in, 7
- Testosterone synthesis  
  autoregulation of, 5  
  by perfused testis, 3
- TF. *See* Transcription factors
- Thyroid hormones  
  and spermatogenesis, 123  
  and testis development, 122–130
- Thyroid-stimulating hormone (TSH), 8  
  in PTU-treated rats, 124
- Thyroxine (T4), in PTU-treated rats, 124
- Tight junctions, 370–371, 399–400, 404
- TK. *See* Tyrosine kinase
- Total sperm count (TSC), intrascrotal temperature and, 449–451
- Transcriptional activating function (TAF), 30–31
- Transcriptional activation domains, of AR, 56–58
- Transcriptional expression patterns, 390–391
- Transcription factors (TF), 47  
  receptor-protein interaction with, 38  
  SR interaction with, 37–38  
  in steroid action, 37–40  
  steroid regulation of, 42–43
- Transducin. *See* G proteins
- Transferrin  
  iron delivery via, 328, 355  
  in spermatogenesis, 315
- Transferrin receptor mRNA levels, in spermatogenesis, 315, 319
- Transferrin synthesis  
  by Sertoli cells, 100, 331, 355  
  testosterone and, 100–103
- Transforming growth factor- $\alpha$  (TGF- $\alpha$ )  
  and Leydig cell steroidogenesis, 154  
  peritubular cell production of, 357
- Sertoli cell production of, 355, 357
- Transforming growth factor- $\beta$  (TGF- $\beta$ )  
  actions of, 328–329, 357  
  CI-MPR binding to, 330  
  peritubular cell production of, 357  
  Sertoli cell production of, 355, 357
- Transgenic mice  
  fertilization defects in, 476  
  insertional mutagenesis in, 476
- Transient hypothyroidism. *See also* Hypothyroidism and testicular development, 123–130
- Triiodothyronine (T3)  
  and IGF-I production, 123  
  in PTU-treated rats, 124
- Tryptophan oxygenase (TO) gene, SREs in, 37
- TSC. *See* Total sperm count
- TSH. *See* Thyroid-stimulating hormone

- Tubulobulbar complexes, in spermatid-Sertoli cell interactions, 340-341
- Tyrosine aminotransferase (TAT) gene, SREs in, 37
- Tyrosine kinase (TK), in acrosome reaction, 462, 469-470
- Tyrophostin RG50864, in stage transition inhibition, 466, 469
- Urea, blood-to-lumen movement of, 370
- Uteroglobin gene, SREs in, 37
- VAP. *See* Average-path velocity
- Vasectomy, and luminal fluid flow rate, 369
- Vasovasostomy, and luminal fluid flow rate, 369
- VCL. *See* Curvilinear velocity
- Vinculin, in ectoplasmic specializations, 180
- Vitamin A deficiency, seminiferous tubule damage by, 358
- Vitamin D<sub>3</sub>, photoperiod-related Sertoli cell response to, 147
- Vitellogenin gene, SREs in, 37-38
- VSL. *See* Straightline velocity
- White-spotting (W) mutation*, and sterility, 474
- Wild type (+)/t complex recombination, 476
- WOB. *See* Wobble
- Wobble (WOB), of sperm motion, 417
- X. *See* Xanthine
- Xanthine (X) + xanthine oxidase (XO)
- ROS production by, 439
  - scavenger protection against, 442
- X-chromosome, and male/female meiosis, 65-66
- X chromosome behavior
- in female gametocytes, 68
  - in spermatogenesis, 67-70
- XO. *See* Xanthine oxidase
- XX germ cells, in testis, 66-67
- XX gonad
- MIS masculinization of, 74-75
  - sex reversal of, 74-75
  - testicular cell differentiation in, 75-82
  - XX gonadal graft, testicular differentiation mechanism in, 83-87
  - XX testicular differentiation induction conditions required for, 83-87
  - gonadal graft age and, 85
  - grafting sites and, 83
  - host kidney tissue interaction, 86
  - host sex/adjacent mesonephros and, 84-85
  - oocyte loss and, 86-87
  - testosterone and, 85
  - time course of, 85-86
- XXY gonocytes
- differentiation path of, 66
  - morphology of, 66
- XXY "Klinefelter" mice, 66-67
- Y chromosome
- and germ-cell differentiation, 66-67
  - during male meiosis, 69-70
  - spermatogenesis role of, 70-71
- Zinc fingers
- nuclear localization signals and, 35-36
  - of SR DN-binding domains, 30, 33, 36-37
- Zona-induced acrosome reaction, 461-470.
- See also* Acrosome reaction; Spontaneous acrosome reaction
- Zona pellucida, 459-460, 462-464
- Zona protein receptors
- alteration of, 488-491
  - identification of, 487-488
- ZP3. *See* Glycoprotein ZP3

